Latest Content

From Lilly's blockbuster earnings to a first-of-its-kind narcolepsy approval, a new mRNA flu vaccine, and a potential mega-merger that would reshape the industry — here's what you need to know.

In today's Pharmaceutical Executive Daily, an antitrust attorney weighs the legal risks of a hypothetical AstraZeneca-Bristol Myers Squibb merger, Eli Lilly beats Wall Street estimates on soaring Mounjaro and Zepbound sales and raises its full-year guidance, and the FDA approves Moderna's first mRNA-based flu vaccine for adults 50 and older.

Ron Lanton, senior partner at Lanton, Lanton & Sosa Law, discusses the legal risks associated with a hypothetical AstraZeneca–Bristol Myers Squibb merger.

FDA has approved Takeda's Orzeyful as the first oral orexin receptor 2 agonist for narcolepsy type 1 in adults.

Eli Lilly posted $23 billion in second-quarter revenue driven by Mounjaro's sales surge to $9.94 billion and Zepbound's $4.93 billion.

The FDA has approved mFLUSIVA (mRNA-1010), Moderna's mRNA-based influenza vaccine, for use in adults 50 and older.

Financials explain BMS' interest, but not why AstraZeneca would accept the risks and scrutiny of the rumored mega-merger discussions.

Krieger Scientific's Joseph Morwald on why over-reliance on AI and under-reliance on human expertise is driving the surge in FDA warning letters.

In today's Pharmaceutical Executive Daily, a senior source denies reports of merger talks between AstraZeneca and Bristol Myers Squibb, CSPC Pharmaceutical and AstraZeneca form a joint venture for biologics manufacturing in China, and a feature examines how U.S. Patent and Trademark Office policy changes are slowing patent challenges for generic and biosimilar drugmakers.

A senior source claims there are no discussions underway between AstraZeneca and Bristol Myers Squibb over a potential combination.

CSPC Pharmaceutical and AstraZeneca have formed a 51:49 joint venture to build a biologics manufacturing facility in Shijiazhuang.

In today's Pharmaceutical Executive Daily, Pathos AI signs licensing deals with Alphamab Oncology and AstraZeneca while Curium agrees to acquire Lantheus for up to $8 billion, Sandoz agrees to a $450 million settlement with 43 U.S. states over generic drug antitrust claims, and a new analysis argues real-time data analytics are essential to managing the growing data burden in clinical trials.

Recent changes at the U.S. Patent and Trademark Office are making it harder to challenge pharmaceutical patents, raising concerns that slower generic and biosimilar competition could undermine efforts to lower drug costs while strengthening protections for brand-name innovators.